HC Wainwright Issues Positive Forecast for KYMR Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Investment analysts at HC Wainwright lifted their Q1 2026 earnings estimates for Kymera Therapeutics in a research report issued to clients and investors on Monday, March 2nd. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.73) for the quarter, up from their prior estimate of ($0.76). HC Wainwright currently has a “Buy” rating and a $134.00 price target on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Kymera Therapeutics’ Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.75) EPS, Q4 2026 earnings at ($0.74) EPS, FY2026 earnings at ($2.96) EPS, FY2027 earnings at ($3.26) EPS, FY2028 earnings at ($3.35) EPS, FY2029 earnings at ($2.64) EPS and FY2030 earnings at $1.34 EPS.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The business had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The firm’s quarterly revenue was down 60.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.88) earnings per share.

Several other research firms also recently weighed in on KYMR. Piper Sandler lifted their target price on Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Barclays lifted their price objective on Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research report on Tuesday, January 27th. Stifel Nicolaus set a $114.00 price objective on Kymera Therapeutics in a research note on Monday, December 8th. Oppenheimer raised their target price on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Kymera Therapeutics Price Performance

Shares of KYMR stock opened at $83.52 on Thursday. The company has a market cap of $6.82 billion, a price-to-earnings ratio of -22.70 and a beta of 2.20. Kymera Therapeutics has a 1 year low of $19.44 and a 1 year high of $103.00. The firm has a fifty day moving average price of $78.75 and a 200-day moving average price of $66.52.

Insider Buying and Selling

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,576 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $88.93, for a total value of $673,733.68. Following the completion of the transaction, the chief financial officer directly owned 237,483 shares in the company, valued at $21,119,363.19. This represents a 3.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Nello Mainolfi sold 100,000 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $89.17, for a total transaction of $8,917,000.00. Following the sale, the chief executive officer owned 660,482 shares in the company, valued at approximately $58,895,179.94. The trade was a 13.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 561,698 shares of company stock worth $50,388,337 in the last quarter. 16.01% of the stock is owned by insiders.

Institutional Trading of Kymera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KYMR. Baker BROS. Advisors LP grew its stake in shares of Kymera Therapeutics by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after purchasing an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC raised its stake in Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after buying an additional 1,124,747 shares in the last quarter. Vanguard Group Inc. raised its stake in Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after buying an additional 845,922 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after buying an additional 1,061,957 shares during the last quarter. Finally, BVF Inc. IL boosted its position in shares of Kymera Therapeutics by 6.6% during the 2nd quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock worth $240,138,000 after acquiring an additional 340,909 shares in the last quarter.

Key Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near‑term loss forecasts across Q1–Q4 2026 (small EPS improvements) and reiterated a Buy with a $134 target — this reduces short‑term downside expectations and supports investor interest. HC Wainwright note
• Positive Sentiment: Recent analyst target increases and bullish notes (including UBS coverage and other upgrades) signal renewed conviction in Kymera’s pipeline and cash runway; these reports are a constructive counterbalance to selling. UBS bullish note
• Positive Sentiment: Some outlets raised Kymera price targets (example: a recent note raising a target to $100), which can attract buyers and provide technical support. Price target update
• Neutral Sentiment: Technical/context: KYMR remains above its 200‑day moving average with elevated volatility (beta ~2.2); analyst consensus targets sit well above the current price, which can amplify both rallies and pullbacks. Market data
• Neutral Sentiment: Institutional activity shows modest position changes among several managers; current flows are not large enough to decisively move the stock by themselves. Institutional holdings
• Negative Sentiment: Large insider selling: Director Bruce Booth sold 81,866 shares (~$7.38M at ~ $90), a substantial, visible transaction that can be perceived as profit‑taking and pressuring the stock. Booth Form 4
• Negative Sentiment: Multiple senior executives (CFO, COO and others) disclosed sales across March 2–4, trimming positions by a few percent each—these repeated insider sales amplify short‑term negative sentiment despite company‑level explanations (e.g., diversification or tax/liquidity needs). Insider filings
• Negative Sentiment: Recent quarterly results (Feb. 26) showed an EPS miss and steep revenue decline year‑over‑year, which remains a fundamental drag on the stock until upcoming clinical milestones or revenue inflection points arrive. Earnings report

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.